Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor

Authors
Publication date
Publisher
Dove Medical Press
Doi
    View on PubMed

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Crossref

      redirect
      oaiinfo:doi/10.2147%2Ftcrm.s23889
      Last time updated on 01/04/2019